222 related articles for article (PubMed ID: 30575978)
21. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
22. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R
Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753
[TBL] [Abstract][Full Text] [Related]
23. MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments.
Scheerens H; Su Z; Irving B; Townsend MJ; Zheng Y; Stefanich E; Chindalore V; Bingham CO; Davis JC
Arthritis Res Ther; 2011; 13(5):R177. PubMed ID: 22029963
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA.
Abdallah H; Hsu JC; Lu P; Fettner S; Zhang X; Douglass W; Bao M; Rowell L; Burmester GR; Kivitz A
J Clin Pharmacol; 2017 Apr; 57(4):459-468. PubMed ID: 27599663
[TBL] [Abstract][Full Text] [Related]
25. A first-in-human pharmacodynamic and pharmacokinetic study of a fully human anti-glucagon receptor monoclonal antibody in normal healthy volunteers.
Kostic A; King TA; Yang F; Chan KC; Yancopoulos GD; Gromada J; Harp JB
Diabetes Obes Metab; 2018 Feb; 20(2):283-291. PubMed ID: 28755409
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus.
Yao Z; Loggia L; Fink D; Chevrier M; Marciniak S; Sharma A; Xu Z
Clin Drug Investig; 2020 Dec; 40(12):1127-1136. PubMed ID: 33085033
[TBL] [Abstract][Full Text] [Related]
27. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants.
Li Y; Zhang H; Pandya H; Miao L; Reid F; Jimenez E; Sadiq MW; Moate R; Lei A; Zhou XH; Kell C; Ding J; Zhang G; Zhao L; Ge X
Clin Pharmacol Drug Dev; 2024 Jun; 13(6):665-671. PubMed ID: 38523487
[TBL] [Abstract][Full Text] [Related]
28. Anti-IL-7 receptor α monoclonal antibody (GSK2618960) in healthy subjects - a randomized, double-blind, placebo-controlled study.
Ellis J; van Maurik A; Fortunato L; Gisbert S; Chen K; Schwartz A; McHugh S; Want A; Santos Franco S; Oliveira JJ; Price J; Coles A; Brown K; Su D; Craigen JL; Yang J; Brett S; Davis B; Cheriyan J; Kousin-Ezewu O; Gray F; Thompson PW; Fernando D
Br J Clin Pharmacol; 2019 Feb; 85(2):304-315. PubMed ID: 30161291
[TBL] [Abstract][Full Text] [Related]
29. First-in-Human Phase 1 Randomized Trial with the Anti-CD40 Monoclonal Antibody KPL-404: Safety, Tolerability, Receptor Occupancy, and Suppression of T-Cell-Dependent Antibody Response.
Samant M; Ziemniak J; Paolini JF
J Pharmacol Exp Ther; 2023 Dec; 387(3):306-314. PubMed ID: 37699709
[TBL] [Abstract][Full Text] [Related]
30. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
31. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
Albach FN; Wagner F; Hüser A; Igel J; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
Eur J Clin Pharmacol; 2018 Feb; 74(2):161-169. PubMed ID: 29127458
[TBL] [Abstract][Full Text] [Related]
32. Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases.
Tanaka Y; Hoshino-Negishi K; Kuboi Y; Tago F; Yasuda N; Imai T
Immunotargets Ther; 2020; 9():241-253. PubMed ID: 33178636
[TBL] [Abstract][Full Text] [Related]
33. In vivo affinity and target engagement in skin and blood in a first-time-in-human study of an anti-oncostatin M monoclonal antibody.
Reid J; Zamuner S; Edwards K; Rumley SA; Nevin K; Feeney M; Zecchin C; Fernando D; Wisniacki N
Br J Clin Pharmacol; 2018 Oct; 84(10):2280-2291. PubMed ID: 29900565
[TBL] [Abstract][Full Text] [Related]
34. Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study.
Boumans MJ; Houbiers JG; Verschueren P; Ishikura H; Westhovens R; Brouwer E; Rojkovich B; Kelly S; den Adel M; Isaacs J; Jacobs H; Gomez-Reino J; Holtkamp GM; Hastings A; Gerlag DM; Tak PP
Ann Rheum Dis; 2012 Feb; 71(2):180-5. PubMed ID: 21917822
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis.
Wei X; Gibiansky L; Wang Y; Fuh F; Erickson R; O'Byrne S; Tang MT
J Clin Pharmacol; 2018 Mar; 58(3):386-398. PubMed ID: 29178491
[TBL] [Abstract][Full Text] [Related]
36. First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers.
Schenk DB; Koller M; Ness DK; Griffith SG; Grundman M; Zago W; Soto J; Atiee G; Ostrowitzki S; Kinney GG
Mov Disord; 2017 Feb; 32(2):211-218. PubMed ID: 27886407
[TBL] [Abstract][Full Text] [Related]
37. Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys.
Vexler V; Yu L; Pamulapati C; Garrido R; Grimm HP; Sriraman P; Bohini S; Schraeml M; Singh U; Brandt M; Ries S; Ma H; Klumpp K; Ji C
MAbs; 2013; 5(5):776-86. PubMed ID: 23924796
[TBL] [Abstract][Full Text] [Related]
38. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study.
Kiessling P; Lledo-Garcia R; Watanabe S; Langdon G; Tran D; Bari M; Christodoulou L; Jones E; Price G; Smith B; Brennan F; White I; Jolles S
Sci Transl Med; 2017 Nov; 9(414):. PubMed ID: 29093180
[TBL] [Abstract][Full Text] [Related]
39. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.
Betts AM; Clark TH; Yang J; Treadway JL; Li M; Giovanelli MA; Abdiche Y; Stone DM; Paralkar VM
J Pharmacol Exp Ther; 2010 Apr; 333(1):2-13. PubMed ID: 20089807
[TBL] [Abstract][Full Text] [Related]
40. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study.
Genovese MC; Van den Bosch F; Roberson SA; Bojin S; Biagini IM; Ryan P; Sloan-Lancaster J
Arthritis Rheum; 2010 Apr; 62(4):929-39. PubMed ID: 20131262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
